Discuss PT-141 on glp1chat
Join the forum to discuss research with other members.
At a glance
PT-141, related to bremelanotide, acts on melanocortin receptors involved in sexual-response signals in the brain. Its action is different from medicines that mainly change blood flow in the body.
Sexual response starts partly in the brain, not only in blood vessels. PT-141 activates melanocortin signaling connected with that central response, which explains why it is studied differently from drugs that mainly widen blood vessels. Clinical evidence for finished bremelanotide products applies to specific people and outcomes. A research preparation with a similar name is not automatically the same product.
Potential benefits & side effects
Interpret each outcome in the context of the study population, formulation and evidence type. Research findings do not establish a personal treatment outcome.
Potential benefits & research findings
Studies address specific sexual-function outcomes and populations. A research-vial preparation should not be assumed equivalent to a regulated finished medicine.[2][1][4]
Read the original publications to see the measured endpoints, comparator, duration and uncertainty. Mechanistic plausibility and a favorable experimental result are different from demonstrated clinical benefit.
Side effects & evidence limitations
Interpret the reported adverse effects together with the study population, route and observation period. Small or short studies can miss uncommon and delayed harms. Evidence from a related compound does not establish the safety of PT-141.
Source-reported adverse effects and cautions
Sources are available for independent reading. Individual claims and research schedules have not yet undergone an independent clinical review by Pep Science.
- Editorial responsibility
- Pep Science editorial desk
- Last independent review
- Not yet recorded
SPECIFICATIONS & SOURCE SCHEDULES
Explore a vial size
Select the exact formulation. Vial content, target dose and prepared concentration are different measurements.
Showing 10 mg · 2 source tables
Standard / Gradual Approach (3 mL = ~3.33 mg/mL)
| Week | Daily Dose (mcg) | Units (per injection) (mL) |
|---|---|---|
| Weeks 1–8 | 500 mcg (0.5 mg) | 15 units (0.15 mL) |
| Weeks 9–12 | 1000 mcg (1.0 mg) | 30 units (0.30 mL) |
| Weeks 13–16 | 1500 mcg (1.5 mg) | 45 units (0.45 mL) |
Route & Frequency: Inject once daily subcutaneously (abdomen or thigh). The subcutaneous route provides approximately 100% bioavailability and is better tolerated than intranasal delivery[2]. The FDA-approved on-demand regimen uses 1.75 mg SC before intercourse (max 8 doses/month)[2]; however, daily protocols at 2.5 mg have been studied in obese women for appetite and weight reduction[3], suggesting daily use can be tolerated. This schedule uses a conservative titration starting below the FDA on-demand dose.
Nasal Actuation Calculation Table (Placeholders)
| Concentration (mcg/mL) | Pump Output (mL/actuation) | Amount per Actuation (mcg) | Actuations per mL | Total Actuations in Reconstituted Volume |
|---|---|---|---|---|
| [A] | [B] | [A] × [B] | 1 / [B] | [Recon. vol. mL] × (1 / [B]) |
| [C] | [D] | [C] × [D] | 1 / [D] | [Recon. vol. mL] × (1 / [D]) |
Additional schedule context & duration
Concise summary of the once-daily regimen.
- Goal: Support sexual desire and arousal through central melanocortin receptor activation[2].
- Schedule: Daily subcutaneous injections for 8–12 weeks (extend to 16 weeks if desired).
- Dose Range: 500–1500 mcg daily with gradual titration.
- Reconstitution: 3.0 mL per 10 mg vial (~3.33 mg/mL) for accurate unit measurements.
- Storage: Lyophilized frozen; reconstituted refrigerated; avoid repeated freeze–thaw.
Suggested daily titration approach.
- Start: 500 mcg daily for the first 8 weeks to assess tolerance.
- Escalate: Increase to 1000 mcg daily during Weeks 9–12.
- Target: 1500 mcg daily during Weeks 13–16 if well tolerated.
- Frequency: Once per day (subcutaneous).
- Timing: Any consistent time; rotate injection sites between abdomen and thighs.
Read this protocol on Pep Science → · View cited documents ↓
Preparation
Reconstitution Steps
- Draw 3.0 mL bacteriostatic water with a sterile syringe.
- Inject slowly down the vial wall; avoid foaming.
- Gently swirl/roll until dissolved (do not shake).
- Label and refrigerate at 2–8 °C (35.6–46.4 °F), protected from light.
Storage Instructions
Proper storage preserves peptide quality.
- Lyophilized: Store at −20 °C (−4 °F) in dry, dark conditions; minimize moisture exposure[8].
- Reconstituted: Refrigerate at 2–8 °C (35.6–46.4 °F); use within approximately 30 days and avoid freeze–thaw.
- Allow vials to reach room temperature before opening to reduce condensation uptake.
Injection Technique
General subcutaneous guidance from clinical best-practice resources[10].
- Clean the vial stopper and skin with alcohol; allow to dry[6].
- Pinch a skinfold; insert the needle at 45–90° into subcutaneous tissue[6][7].
- Do not aspirate for subcutaneous injections; inject slowly and steadily[6].
- Rotate sites systematically (abdomen, thighs) to avoid lipohypertrophy[5][10].
- Discard needles and syringes in a sharps container after one use[6].
Materials & quantity planning
Source materials checklist · 10 mg
Plan based on an 8–16 week daily protocol with gradual titration.
-
Peptide Vials (PT-141, 10 mg each):
- 8 weeks (56 days × 500 mcg = 28 mg) ≈ 3 vials
- 12 weeks (56 × 500 + 28 × 1000 = 56 mg) ≈ 6 vials
- 16 weeks (56 × 500 + 28 × 1000 + 28 × 1500 = 98 mg) ≈ 10 vials
-
Insulin Syringes (U-100):
- Per week: 7 syringes (1/day)
- 8 weeks: 56 syringes
- 12 weeks: 84 syringes
- 16 weeks: 112 syringes
-
Bacteriostatic Water (10 mL bottles): Use ~3.0 mL per vial for reconstitution.
- 8 weeks (3 vials): 9 mL → 1 × 10 mL bottle
- 12 weeks (6 vials): 18 mL → 2 × 10 mL bottles
- 16 weeks (10 vials): 30 mL → 3 × 10 mL bottles
-
Alcohol Swabs: One for the vial stopper + one for the injection site each day.
- Per week: 14 swabs (2/day)
- 8 weeks: 112 swabs → recommend 2 × 100-count boxes
- 12 weeks: 168 swabs → recommend 2 × 100-count boxes
- 16 weeks: 224 swabs → recommend 3 × 100-count boxes
Calculate a phased quantity
Enter each finite phase from the schedule you are studying. Open-ended phases need an explicit duration. Calculation uses 10 mg per vial and 3 mL per vial.
Complete each phase to calculate totals.
Quantity estimates exclude preparation losses and expiry. Follow the formulation’s handling and disposal requirements.
FOLLOW THE EVIDENCE
References & further reading
Original publications and source documents cited across this product’s variants. A listed source is not an independent endorsement of a dosing schedule.
- 02
Research publication
PMC (2022) — Bremelanotide for treatment of female hypoactive sexual desire: mechanism, trials, and safety review (opens in a new tab)pmc.ncbi.nlm.nih.gov
Back to overview ↑ - 04
Source document
Mayo Clinic — Bremelanotide (subcutaneous route): side effects, dosage, and precautions (opens in a new tab)www.mayoclinic.org
Back to overview ↑ - 05
Public health resource
MedlinePlus — Patient instructions for subcutaneous injections: site rotation and technique (opens in a new tab)medlineplus.gov
Back to overview ↑ - 06
Public health resource
CDC — Vaccine administration: subcutaneous route (angle, site, and no-aspiration guidance) (opens in a new tab)www.cdc.gov
Back to overview ↑ - 07
Public health resource
CDC — Vaccine administration best practices: during the injection (technique diagram) (opens in a new tab)www.cdc.gov
Back to overview ↑ - 08
Public health resource
CDC — Storage and handling of immunobiologics: cold-chain and lyophilized product guidance (opens in a new tab)www.cdc.gov
Back to overview ↑ - 09
Research publication
PMC (2019) — Bremelanotide: first approval (comprehensive drug profile including cardiovascular considerations) (opens in a new tab)pmc.ncbi.nlm.nih.gov
Back to overview ↑ - 10
Public health resource
NCBI Bookshelf — Best practices for injection (asepsis, preparation, and administration) (opens in a new tab)www.ncbi.nlm.nih.gov
Back to overview ↑ - 15
Research publication
Subcutaneous Drug Injection Review (PMC) — Pharmacologic considerations of the subcutaneous route (opens in a new tab)pmc.ncbi.nlm.nih.gov
Back to overview ↑
Continue exploring
Related topics are not interchangeable compounds or formulations.